Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India.

ABSTRACT:

Background

Majority of patients of hepatocellular carcinoma (HCC) in India present in advanced stages, when curative treatment options are limited. We undertook this study to assess the cost-effectiveness of treating advanced HCC patients with sorafenib compared with best supportive care (BSC).

Methods

A Markov model was parameterized to model the lifetime costs and consequences of treating advanced HCC patients with sorafenib versus BSC using a societal perspective. Cost of routine care, diagnostics, management of complications in both the arms and management of adverse effects of sorafenib treatment were considered. A probabilistic sensitivity analysis was undertaken to assess the effect of parameter uncertainty.

Results

The incremental cost and benefit gained by tr

SUBMITTER: Gupta N 

PROVIDER: S-EPMC6728525 | biostudies-literature | 2019 Jul-Aug

REPOSITORIES: biostudies-literature